Since the nuclear localization of FBP1 in pancreatic cancer is crucial for the sensitivity of pancreatic cancer to PARP inhibitors, the regulatory mechanism by which FBP1 is translocated to the nucleus needs to be further studied. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.